Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron Corporation (Nasdaq: GERN) today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. Data on the first two patients were presented at the 2011 International Conference on Spinal Cord Medicine and Rehabilitation in Washington, D.C. A second presentation was given at the 2011 Spine Symposium, which was held as part of The American Spinal Injury Association (ASIA) Annual Scientific Meeting. The presentations were given by Edward Wirth, III, M.D., Ph.D., Geron's Medical Director for Cell Therapies and Linda Jones, P.T., M.S., Geron's Senior Clinical Trials Manager for GRNOPC1.

"We are pleased to report a very good safety profile of GRNOPC1 to date, with no serious adverse events," said Dr. Wirth. "Currently, we have two patients in the trial. We anticipate increased enrollment going forward as we open our additional clinical sites and following FDA approval to expand our inclusion criteria to patients with injuries resulting in a neurological level of T11, which represents a substantial percentage of thoracic injuries, and to reduce the stagger between patients from 30 days to 10 days."

Source:

 Geron Corporation

Comments

  1. Jay Lenner Jay Lenner United States says:

    http://youtu.be/Xoj-ukphUrM - Video from Juan Carlos Murillo, a commercial airline pilot who suffered a complete spinal cord injury (ASIA A) and was  told by his doctors that he would never walk or fly again.  After receiving stem cells, he's now walking, driving, flying and just passed his commercial pilot's physical examination. The results are also published in the International Archives of Medicine: www.intarchmed.com/content/pdf/1755-7682-3-30.pdf

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
T cell behavior informs metastatic melanoma outcomes